The global Inhalation Anesthesia Market size is expected to reach USD 2.4 billion by 2030 and is expected to expand at a CAGR of 9.0% in the forecast period, from 2022 to 2030, according to a new report by Grand View Research, Inc. Inhalation anesthetics offer shorter induction period and recovery time along with better efficacy and lesser adverse effects as compared to other alternatives, thus providing better anesthetic effect during surgical procedures. They also provide excellent control over the duration of anesthesia in the patient. Thus, inhalation anesthesia is being preferred over intravenous anesthesia due to these advantages.
Drugs administered through inhalation anesthesia have
a quick onset of action even at low dose as compared to intravenous anesthesia.
Using inhalation route for administration helps avoid excessive dosage and
keeps the patient’s autonomic functions intact. As these drugs are eliminated
via lungs, they have lower chances of accumulation in the body. Hence, they
result in lower risk of hepatotoxicity. In addition, drugs administered through
inhalation route have limited tolerance and addiction level as compared to
other alternatives routes.
With the launch of innovative respiratory products
such as AnaConDa (Anaesthetic Conserving Device), administration of inhalation
general anesthetic agents such as sevoflurane, isoflurane, & other agents
have become easier. Inhalation anesthesia is considered to be the best
alternative for patients who are on ventilation for more than 24 hours as it
becomes easy to monitor the patient’s health.
Major concern associated with anesthetic gas is that
only 5% account for patient use and the rest 95% is released in the atmosphere,
which leads to greenhouse effect of these gases. The comparative analysis of
sevoflurane, isoflurane, and desflurane based on atmospheric time span and
global atmospheric concentrations indicates that desflurane poses a high
potential threat for environment.
Related Press Release@ Inhalation Anesthesia Market Report
Inhalation Anesthesia Market
Report Highlights
- Sevoflurane held the largest market share in 2021 due to the fact
that its pharmacokinetics and pharmacodynamics leads to many advantages
over other alternate inhaled anesthetic agents available.
- Desflurane, alone or in combination with nitrous oxide or other
inhalation anesthetic agents is used in various surgical procedures owing
to its rapid onset of action and elimination rate; therefore, driving the
segment demand.
- There have been many complications reported with halothane, for
instance, halothane-induced hepatitis; therefore, this anesthetic agent
has been discontinued in the majority of the western countries.
- North America dominated the market in 2021 due to the high demand
for sevoflurane and desflurane in the region. Key companies are also
undertaking various strategic initiatives that has led to their high
revenue growth in the U.S.
- China is the largest economy in Asia Pacific. It is a country with
the maximum population in the world, hence having a large patient pool for
surgeries. A large number of surgeries being performed along with the
presence of a large patient pool is anticipated to boost the market over
the forecast period.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment